AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00114738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
Study NCT00114738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
Study NCT00114738 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib or observation
Description: At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: HDM201 120mg, Every 3 weeks, Per os
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib, 60 mg /day, continuous, Per os
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib, 600mg twice daily, Per os
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg/day, continuous, Per os
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice daily, Per os
Study NCT04116541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: 300 mg/day,continuous, Per os
Study NCT00507351 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 3 questionnaires that will take 20 minutes total to complete.
Study NCT01711775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Single oral dose Day 1, repeated oral dose once daily Days 5-14
Study NCT03921359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMARTfit training
Description: For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.
Study NCT03921359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical training
Description: For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
Study NCT01037036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Punctal Plug Delivery System
Description: To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
Study NCT01037036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
Study NCT03535532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral laparoscopic adrenalectomy
Description: unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
Study NCT03535532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical treatment
Description: standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
Study NCT03330366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allium hookeri extract
Description: take two capsules per day (486 mg/day) for 8 weeks
Study NCT03330366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take two capsules per day
Study NCT02338466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rt-PA
Description: 0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
Study NCT02338466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: 0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
Study NCT02338466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenecteplase
Description: Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg).
Study NCT02003989 — intervention group
Intervention type: OTHER
Intervention: ophthalmologic examination and MRI
Description: thorough investigation of patients, not included in usual care.
Study NCT03689101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsies
Description: Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
Study NCT03677934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.
Study NCT03677934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Injections of 10 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.
Study NCT04583358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMT-101 (oral)
Description: AMT 101 is orally administered biological therapeutic taken once daily
Study NCT04583358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (oral)
Description: Orally administered placebo comparator taken once daily
Study NCT00718068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Potassium Chloride Concentrate
Description: Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
Study NCT00718068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Potassium Chloride Concentrate
Description: By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
Study NCT04328415 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cerebral scintigraphy
Description: Radioactive tracer 99mTc-DTPA
Study NCT02567864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Beat Accupunch exercise program
Description: HBA has three phases and takes 40 minutes to complete.
Study NCT02567864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: participants maintain their daily activities.
Study NCT00003178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT01173640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol (single dose)
Description: 1 g oral dose
Study NCT01173640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol (multiple dose)
Description: 1 g oral dose for 8 days
Study NCT03276663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Formula feeding regimen
Description: The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
Study NCT03621982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-301
Description: intravenous infusion
Study NCT03621982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous infusion
Study NCT01157143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRP0038 (NV1FGF)
Description: Pharmaceutical form : solution~Route of administration : intramuscular
Study NCT02963051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Description: 1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
Study NCT02963051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: 80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals
Study NCT02963051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Description: 1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals
Study NCT01342887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV
Study NCT01342887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: Given PO
Study NCT01342887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT01342887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01342887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative studies
Study NCT03722719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Knack
Description: The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
Study NCT03722719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
Study NCT03722719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Knack + PFMT
Description: These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
Study NCT02221323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO
Study NCT03434613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5mg 1T daily for 6 months
Study NCT03434613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/ezetimibe combination
Description: Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
Study NCT02450019 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional to protective ventilation
Description: Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
Study NCT02450019 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective to traditional ventilation
Description: Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
Study NCT00663962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
Study NCT00663962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
Study NCT02754414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis platelet collection
Description: A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
Study NCT02754414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refrigerated storage of apheresis platelets in PAS/plasma
Description: The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
Study NCT02754414 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Infusion of aliquot of autologous radiolabeled platelets
Description: Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
Study NCT02754414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vitro tests
Description: Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
Study NCT03119337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text-based follow-up
Description: 2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
Study NCT02922985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetominophen
Description: One dose if 1 gram intravenous to be given pre-surgery
Study NCT02922985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac, intramuscular
Description: One dose of 60 mg Intramuscular to be given at time of skin closure
Study NCT02922985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, subcutaneous
Description: Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
Study NCT02922985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
Study NCT03813732 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: orbital fracture
Description: using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area
Study NCT01874665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg, tablets, orally, once-daily.
Study NCT04693845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality
Description: CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings.
Study NCT04693845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
Study NCT01860807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Study NCT01860807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00003178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Study NCT00823446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revera Wound Care
Description: Revalesio Part Number MDW0060
Study NCT00823446 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sodium Chloride for Irrigation
Study NCT03146897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Food
Description: Supplementary food for treating MAM
Study NCT03019198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: Intravenous 15 mg per kilogram tranexamic acid
Study NCT03019198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Study NCT02716077 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET/CT imaging
Study NCT02794714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromuscular blockade
Description: Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
Study NCT02794714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade
Description: Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
Study NCT03463434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Fluidized Therapy
Description: AFT bed used for pressure injury treatment
Study NCT00003178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study NCT03218605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
Study NCT00649233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
Description: 100/50mg, single dose fed
Study NCT00649233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopressor HCT® Tablets 100/50 mg
Description: 100/50mg, single dose fed
Study NCT03279354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Move app intervention
Description: All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
Study NCT03279354 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HK FitNuts app intervention
Description: The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics \& Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week.
Study NCT03924505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organize and Mobilize for Implementation Effectiveness
Description: Our trial is trying to understand how a multi-faceted, facilitation-based implementation strategy advances effective implementation of naloxone within syringe services programs